GlassScriptPhysician profile
Archana Swami
NPI 1326248519
$4,204.48
in general payments reported to CMS, 2019-2025
29 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $773 · 2023: $917 · 2024: $946 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127 · Long Term Medical Supply Or Device Loan: $110 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.25 |
| Long Term Medical Supply Or Device Loan | $109.98 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $585.76 | 2022-2025 | Tepezza, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $429.27 | 2021-2025 | |
| Novo Nordisk INC | $408.95 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Abbott Laboratories | $279.67 | 2021-2025 | Freestyle Libre 3, Freestyle Copilot |
| Neurocrine Biosciences, INC. | $251.13 | 2024-2025 | |
| Sequel Med Tech, LLC | $206.11 | 2025 | Twiist |
| Abbvie INC. | $206.03 | 2021-2025 | Synthroid, Ubrelvy |
| Medtronic, INC. | $190.57 | 2024-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.78 | 2023-2025 | Jardiance, Synjardy |
| Intuity Medical INC | $159.20 | 2022 | |
| Ibsa Pharma INC. | $151.45 | 2022-2025 | Tirosint, Licart, Flector |
| Sanofi-Aventis U.S. LLC | $141.89 | 2022-2024 | |
| Amryt Pharma Holdings LTD | $141.50 | 2023 | Mycapssa |
| Xeris Pharmaceuticals, INC. | $135.05 | 2025 | Recorlev |
| Recordati_rare_diseases_inc. | $99.04 | 2023-2025 | Isturisa, Signifor Lar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $98.73 | 2022-2025 | Unithroid |
| Mannkind Corporation | $96.58 | 2022-2023 | Afrezza |
| Lilly USA, LLC | $78.85 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $59.08 | 2021-2023 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $57.96 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $47.68 | 2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $46.10 | 2022 | |
| Insulet Corporation | $33.45 | 2021-2023 | Omnipod |
| Corcept Therapeutics | $33.21 | 2021-2025 | Korlym |
| Beta Bionics, INC. | $31.63 | 2023-2024 | Ilet Bionic Pancreas |
| Astellas Pharma US INC | $24.85 | 2024 | Veozah |
| Antares Pharma, INC. | $21.43 | 2023 | Nocdurna, Tlando, Xyosted |
| Verity Pharmaceuticals INC. | $15.03 | 2025 | Tlando |
| Zealand Pharma US, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Swami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.